Anna Wienner – General Manager, IBSA Hungary
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
IBSA Institut Biochimique SA is a privately owned, pharmaceutical company founded in 1945 by a group of Swiss biologists. Based in Lugano, Switzerland, IBSA started its activities at a national level but rapidly became a well consolidated company worldwide. IBSA markets its products in 4 continents which means more than 70 countries, including the US. IBSA’s history can be divided into 2 main periods from its beginning 1945 to 1985 when the current management took over and completely re-defined the company strategy leading to the first international development and to its present global reputation.
As a result of this massive commercial revolution, IBSA currently has a head count of about 1800 employees and its products cover 7 main therapeutic areas in 4 continents and more than 70 countries. Each year the company manufactures about 12 millions vials of hormones, more than 200 millions soft gel capsules and about 60 millions packages of finished products. These are the numbers of a well-deserved success.
The company’s first foreign subsidiary was founded in 1995 in Budapest, Hungary. The subsidiary has 21 years of unbroken success, with a dedicated and hardworking staff whose efforts truly demonstrate the impeccable quality and competitive prices that the IBSA brand embodies.
Contact
1124 Budapest, Fodor u. 54 / B
Tel: (1) 225-7775
Fax: (1) 201-7772
Email: ibsa@ibsa.hu
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
To effectively reform old habits requires diligence, consistency and, above all, patience. As an introduction for our readers, could you describe the initial objectives that you set for yourself…
One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If…
Hungary operates under a state-owned universal National Health Insurance Fund (OEP), completely financed through mandatory tax contributions from employers and employees. “From a drug reimbursement point of view, we have…
Hungarian collector and producer of blood plasma and plasma-derived therapies HUMAN BioPlazma is rooted in over 60 years of history within the country, but only in 2008, with the influence…
While pharmaceutical products and healthcare financing dominate the majority of discussions surrounding the improvement of health outcomes, health literacy still remains a core issue that, if left unaddressed, may vary…
Preventive healthcare and health literacy are core issues in Hungary that, if left unaddressed, may hinder the country’s ability to push its health agenda forward and create a more sustainable…
Smaller pharma companies in Hungary are looking to new unconventional methods of OTC promotion to sidestep the country’s somewhat restrictive reimbursement scheme and compete with major players in the market. Especially in…
The President of the Doctoral Council of Semmelweis University, Dr. József Timár provides an overview of the healthcare system in Hungary with particular reference to oncology and describes the challenges…
LEO Pharma Hungary’s Andrea Bondár demonstrates the significance of adopting non-traditional methods of promotional activities, and defines how a true intent on understanding the psyche of patients suffering from chronic…
Anita Ordog, GM of Angelini Hungary, discusses the affiliate’s history in the country, their expanding OTC and specialty products portfolio, targeted marketing and sales strategies, and Angelini’s challenging entrance into…
Dr. Lívia Ilku, director of Hungary’s main domestic pharmaceutical manufacturers’ association (MAGYOSZ), describes the current priorities of its member companies and the key factors for success in Hungary; specifically innovation…
Prof. Dr. István Vályi-Nagy, Director General of the United St. Istvan and St. Laszlo Hospitals, shares his insights on running one of the largest hospitals in Hungary and the challenges…
The Managing Director of HUMAN BioPlazma, Ákos Tóth, highlights the transformational growth that the business has experienced since becoming a part of Kedrion Biopharma in 2008, while pinpointing the strategic…
See our Cookie Privacy Policy Here
